BusinessAdmin•Yahoo Finance RSS•6 hours ago
Truist Lowers Price Target for Viridian Therapeutics to $36
Truist has reduced its price target for Viridian Therapeutics, indicating a shift in market outlook.
- • Truist has revised its price target for Viridian Therapeutics (VRDN) from $40 to $36.
- • The adjustment reflects changes in market conditions and company performance expectations.
- • Investors should consider this new target when evaluating their positions in Viridian Therapeutics.
Source: Yahoo Finance RSS
Read original →
